Vitamin E analogues: a new class of inducers of apoptosis with selective anti-cancer effects

In spite of unrelenting effort, the net incidence of neoplastic diseases appears not to have been curbed. While some types of cancer have been suppressed significantly, others are either stagnating or on the increase. Therefore, the need for a cure is imperative, in particularly a drug or combinatio...

Full description

Saved in:
Bibliographic Details
Published inCurrent cancer drug targets Vol. 4; no. 4; p. 355
Main Authors Neuzil, Jiri, Tomasetti, Marco, Mellick, Albert S, Alleva, Renata, Salvatore, Brian A, Birringer, Marc, Fariss, Marc W
Format Journal Article
LanguageEnglish
Published Netherlands 01.06.2004
Subjects
Antineoplastic Agents - therapeutic use
Antioxidants - therapeutic use
Apoptosis - drug effects
Humans
Neoplasms - drug therapy
Vitamin E - analogs & derivatives
Vitamin E - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:In spite of unrelenting effort, the net incidence of neoplastic diseases appears not to have been curbed. While some types of cancer have been suppressed significantly, others are either stagnating or on the increase. Therefore, the need for a cure is imperative, in particularly a drug or combination of drugs that would be selective for malignant cells, i.e. with as low secondary toxicity as possible. Recent data strongly suggest that analogues of vitamin E, epitomised by the most studied alpha-tocopheryl succinate (alpha-TOS), may meet the need for the coveted drugs with a selective anti-neoplastic effect. The reasons for this optimism are reviewed in this article.
ISSN:1568-0096
DOI:10.2174/1568009043332943